BerGenBio Announces Abstracts Accepted for Presentation at 2023 ASCO
- Oral presentation to reveal data from trial evaluating bemcentinib in relapsed mesothelioma - - Trial-in-Progress poster to be presented regarding the BGBC016 1L STK11m NSCLC trial - BERGEN, Norway, May 25, 2023 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical needs, today announced that the Company will be presenting two abstracts at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago June 2-6, 2023. An oral presentation will highlight the